Cure8 research brief
Predicting which patients with acute severe ulcerative colitis will need colectomy or will not respond to steroids can guide early treatment decisions. This study shows that important predictors differ between East Asian and Western (ANZ/European) patients, so one-size-fits-all risk scores may mislead care.
Clinicians treating acute severe ulcerative colitis, researchers developing prediction models or biomarkers, and patients (or caregivers) interested in risk factors for steroid non-response or surgery—especially those on or with prior exposure to biologic therapies.
The researchers retrospectively analyzed 826 ASUC patients from 23 referral hospitals (411 East Asian, 415 ANZ) to build models predicting 1-year colectomy and non-response to corticosteroids.
In the East Asian cohort, factors linked to higher 1-year colectomy risk included female sex, prior exposure to tumor necrosis factor (TNF) inhibitors, and low admission albumin. Predictors of steroid non-response in East Asian patients included younger age at diagnosis, baseline steroid use, very low admission albumin, and extraintestinal manifestations.
The East Asian–derived scores performed well within the East Asian group but had limited utility in the ANZ cohort. Conversely, European-derived scores predicted outcomes accurately in the ANZ cohort but were less predictive in East Asian patients.
That pattern persisted after propensity-score matching, supporting a true population difference rather than simple case-mix effects. What this means practically: prediction tools for ASUC may need to be population-specific. Clinicians should be cautious applying scores developed in one region to patients from another without local validation.
This is a retrospective multicenter study using data from 2015–2022 and includes external validation across regions. The findings support the need for region-specific validation of prognostic tools; they do not by themselves prove causal mechanisms. The study uses routinely available clinical data (including albumin) rather than novel biomarkers.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Knowing a patient’s estimated infliximab clearance before starting rescue therapy for acute severe ulcerative colitis could help identify who may need higher or intensified induction dosing and who might be at greater...
Lowering the CRP cutoff could help hospitals identify hospitalized UC patients at higher risk of needing surgery who are currently classified as less severe. That may affect monitoring and treatment decisions during...
The T&W criteria are still used to define severe UC on admission, but relying on them alone may delay recognition of steroid non‑response and escalation decisions. Integrating biomarkers, endoscopy, and imaging can help...
